IPSWICH, Mass., Feb. 4 /PRNewswire/ -- As an important supplier to the Wellcome Trust Sanger Institute, New England Biolabs is pleased to announce that the Sanger Institute will use New England Biolabs as one of its suppliers for next-generation sequencing library construction reagents.
"We are extremely pleased that the Wellcome Trust Sanger Institute, as a world leading genome center, has determined that our reagents meet their high standards," stated Peter Nathan, Director of Global Business Development at New England Biolabs.
NEBNext™ DNA Sample Prep Reagent Sets contain enzymes and buffers that are ideally suited for sample preparation for next generation sequencing, as well as the preparation of expression libraries. Reagents are available for each step of library construction workflow and are compatible with the Illumina® GAII, Roche/454 GS FLX Titanium™ and the Life SOLiD™ 3 platforms. These sets are highly cost effective and each of the components must pass rigorous quality control and functional validation.
Established in mid 1970s, New England Biolabs, Inc. leads the industry in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, cellular analysis and RNA analysis. Additionally, NEB is focusing on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com.
Illumina is a registered trademark of Illumina, Inc.
GS FLX Titanium is a trademark of Roche.
SOLiD is a trademark of Life Technologies.
SOURCE New England Biolabs, Inc.
|SOURCE New England Biolabs, Inc.|
Copyright©2010 PR Newswire.
All rights reserved